Skip to content

Free cash flow at other companies

LivaNova logo
LivaNovaLIVN
$926K-93.0%
ICU Medical logo
ICU MedicalICUI
$27.61M-24.8%
Edwards Lifesciences logo
Edwards LifesciencesEW
-$21.1M-109%
OSI Systems logo
OSI SystemsOSIS
$6.9M-91.1%
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Calculated from TransMedics Group, Inc.’s reported figures.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s free cash flow?
TransMedics Group, Inc. (TMDX) reported free cash flow of -$12.12M in Q1 2026.
How has TransMedics Group, Inc.'s free cash flow changed year-over-year?
TransMedics Group, Inc.'s free cash flow increased by 59.4% year-over-year, from -$29.89M to -$12.12M.
What is the long-term trend for TransMedics Group, Inc.'s free cash flow?
Over 3 years (2021 to 2025), TransMedics Group, Inc.'s free cash flow has grown at a 60.4% compound annual growth rate (CAGR), from -$32.38M to $133.59M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.